{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:22:09Z","timestamp":1790810529277,"version":"4.1.0"},"reference-count":21,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2026,2,1]]},"abstract":"\n Importance<\/jats:title>\n Human papillomavirus (HPV) vaccination has been associated with reduced risk of high-grade cervical lesions. However, evidence on its association with high-grade vulvovaginal lesions remains scarce.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate the association between quadrivalent HPV vaccination and high-grade vulvovaginal lesions and assess the population-level incidence reduction among birth cohorts eligible for various vaccination programs.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This population-based cohort study included women who were born between 1985 and 1998 and resided in Sweden between 2006 and 2022. Eligible participants had not previously received an HPV vaccination and did not have high-grade vulvovaginal lesions. Data were analyzed from February to October 2025.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n HPV vaccination status was treated as a time-varying exposure, and birth cohorts corresponded to different vaccination programs: 1985 to 1988 (opportunistic vaccination program), 1989 to 1992 (subsidized vaccination), and 1993 to 1998 (catch-up vaccination).<\/jats:p>\n <\/jats:sec>\n \n Main Outcome and Measures<\/jats:title>\n The main outcome was incidence of high-grade vulvovaginal lesions, including cancers. Poisson regression models were used to estimate incidence rate ratios with 95% CIs.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Among 778\u202f943 women, a total of 256\u202f353 (32.9%) received at least 1 dose of the quadrivalent HPV vaccine. The median (IQR) follow-up duration was 17.0 (17.0-17.0) years for unvaccinated women, 12.2 (10.6-13.4) years for those vaccinated between ages 10 and 16 years, and 10.8 (9.3-13.5) years for those vaccinated at 17 years or older. During follow-up, 98 cases of high-grade vulvovaginal lesions were found in vaccinated women, and 547 cases were found in unvaccinated women. Compared with unvaccinated women, the fully adjusted incidence rate ratio of high-grade vulvovaginal lesions was 0.63 (95% CI, 0.50-0.81) in vaccinated women. Stratified by age at vaccination, the incidence rate ratios for those vaccinated at 10 to 16 years and 17 years or older were 0.45 (95% CI, 0.32-0.65) and 0.80 (95% CI, 0.61-1.06), respectively. Compared with women born between 1985 and 1988, the incidence rate ratios for those born in 1989 to 1992 and 1993 to 1998 were 0.81 (95% CI, 0.67-0.97) and 0.62 (95% CI, 0.49-0.80), respectively.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cohort study, vaccinated women had a lower incidence of high-grade vulvovaginal lesions compared with unvaccinated women, with a greater incidence reduction for those vaccinated at younger ages (before 17 years of age). Population-level incidence reduction was observed in cohorts vaccinated through subsidized or catch-up programs. These findings support that scaling up coverage of HPV vaccination at younger ages may help prevent high-grade vulvovaginal lesions.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamaoncol.2025.5511","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T16:00:19Z","timestamp":1766073619000},"page":"177","source":"Crossref","is-referenced-by-count":3,"title":["Quadrivalent Human Papillomavirus Vaccine and High-Grade Vulvovaginal Lesions"],"prefix":"10.1001","volume":"12","author":[{"given":"Yunyang","family":"Deng","sequence":"first","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiqiang","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden"},{"name":"Unit of Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina Schollin","family":"Ask","sequence":"additional","affiliation":[{"name":"Unit for Vaccination Programmes, Department of Public Health Analysis and Data Management, Public Health Agency of Sweden, Solna, Sweden"},{"name":"Department of Women\u2019s and Children\u2019s Health, Karolinska Institutet, Stockholm, Sweden"},{"name":"Sachs\u2019 Children and Youth Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiia","family":"Lepp","sequence":"additional","affiliation":[{"name":"Unit for Vaccination Programmes, Department of Public Health Analysis and Data Management, Public Health Agency of Sweden, Solna, Sweden"},{"name":"Unit for Immunization, Department of Communicable Disease Control and Health Protection, Public Health Agency of Sweden, Solna, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Clements","sequence":"additional","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Milerad","sequence":"additional","affiliation":[{"name":"Regional Cancer Center - Stockholm and Gotland Region, Stockholm, Sweden"},{"name":"Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Carlander","sequence":"additional","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden"},{"name":"Department of Infectious Diseases, Karolinska University Hospital, Huddinge, Sweden"},{"name":"Department of Medicine Huddinge, Karolinska Institutet, Huddinge, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayao","family":"Lei","sequence":"additional","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden"},{"name":"Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"key":"coi250076r1","doi-asserted-by":"publisher","first-page":"F55","DOI":"10.1016\/j.vaccine.2012.06.083","article-title":"The biology and life-cycle of human papillomaviruses.","volume":"30","author":"Doorbar","year":"2012","journal-title":"Vaccine"},{"issue":"4","key":"coi250076r2","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/ijc.30716","article-title":"Worldwide burden of cancer attributable to HPV by site, country and HPV type.","volume":"141","author":"de Martel","year":"2017","journal-title":"Int J Cancer"},{"key":"coi250076r4","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ypmed.2018.12.014","article-title":"Mode of HPV vaccination delivery and equity in vaccine uptake: a nationwide cohort study.","volume":"120","author":"Wang","year":"2019","journal-title":"Prev Med"},{"key":"coi250076r5","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.101178","article-title":"Effectiveness of quadrivalent human papillomavirus vaccination against high-grade cervical lesions by age and doses: a population-based cohort study.","volume":"49","author":"Wu","year":"2025","journal-title":"Lancet Reg Health Eur"},{"issue":"14","key":"coi250076r6","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1056\/NEJMoa1917338","article-title":"HPV vaccination and the risk of invasive cervical cancer.","volume":"383","author":"Lei","year":"2020","journal-title":"N Engl J Med"},{"issue":"11","key":"coi250076r7","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1080\/14760584.2019.1692658","article-title":"Prophylactic vaccination against human papillomaviruses to prevent vulval and vaginal cancer and their precursors.","volume":"18","author":"Xu","year":"2019","journal-title":"Expert Rev Vaccines"},{"issue":"7","key":"coi250076r8","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1093\/jnci\/djaa209","article-title":"Real-world effectiveness of human papillomavirus vaccination against vulvovaginal high-grade precancerous lesions and cancers.","volume":"113","author":"Dehlendorff","year":"2021","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"coi250076r9","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s10654-009-9350-y","article-title":"The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research.","volume":"24","author":"Ludvigsson","year":"2009","journal-title":"Eur J Epidemiol"},{"issue":"7","key":"coi250076r11","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/pds.1294","article-title":"The new Swedish Prescribed Drug Register\u2013opportunities for pharmacoepidemiological research and experience from the first six months.","volume":"16","author":"Wettermark","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"coi250076r12","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1186\/1471-2458-11-450","article-title":"External review and validation of the Swedish national inpatient register.","volume":"11","author":"Ludvigsson","year":"2011","journal-title":"BMC Public Health"},{"issue":"1","key":"coi250076r13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1080\/02841860802247664","article-title":"The completeness of the Swedish Cancer Register: a sample survey for year 1998.","volume":"48","author":"Barlow","year":"2009","journal-title":"Acta Oncol"},{"issue":"2","key":"coi250076r14","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s10654-016-0117-y","article-title":"Registers of the Swedish total population and their use in medical research.","volume":"31","author":"Ludvigsson","year":"2016","journal-title":"Eur J Epidemiol"},{"issue":"9","key":"coi250076r15","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s10654-017-0316-1","article-title":"The Swedish cause of death register.","volume":"32","author":"Brooke","year":"2017","journal-title":"Eur J Epidemiol"},{"issue":"4","key":"coi250076r16","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s10654-019-00511-8","article-title":"The longitudinal integrated database for health insurance and labour market studies (LISA) and its use in medical research.","volume":"34","author":"Ludvigsson","year":"2019","journal-title":"Eur J Epidemiol"},{"key":"coi250076r17","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/978-1-59745-423-0","article-title":"The Swedish Multi-generation Register.","volume":"675","author":"Ekbom","year":"2011","journal-title":"Methods Mol Biol"},{"issue":"5","key":"coi250076r18","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/j.1600-0412.2010.01066.x","article-title":"Women\u2019s sexual behavior. Population-based study among 65,000 women from four Nordic countries before introduction of human papillomavirus vaccination.","volume":"90","author":"Jensen","year":"2011","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"2","key":"coi250076r19","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2023.2239085","article-title":"Human papillomavirus vaccine effectiveness by age at vaccination: a systematic review.","volume":"19","author":"Ellingson","year":"2023","journal-title":"Hum Vaccin Immunother"},{"issue":"13","key":"coi250076r20","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1016\/j.ejca.2015.06.001","article-title":"Human papillomavirus genotype attribution for HPVs 6, 11, 16, 18, 31, 33, 45, 52 and 58 in female anogenital lesions.","volume":"51","author":"Serrano","year":"2015","journal-title":"Eur J Cancer"},{"issue":"1","key":"coi250076r21","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/sj.bjc.6603822","article-title":"Lifestyle and socio-demographic factors associated with high-risk HPV infection in UK women.","volume":"97","author":"Cotton","year":"2007","journal-title":"Br J Cancer"},{"key":"coi250076r3","unstructured":"Public Health Agency of Sweden. HPV vaccination in Sweden 2007-2017. Accessed May 6, 2025. https:\/\/www.folkhalsomyndigheten.se\/folkhalsorapportering-statistik\/statistikdatabaser-och-visualisering\/vaccinationsstatistik\/statistik-for-hpv-vaccinationer\/\"https:\/\/www.folkhalsomyndigheten.se\/folkhalsorapportering-statistik\/statistikdatabaser-och-visualisering\/vaccinationsstatistik\/statistik-for-hpv-vaccinationer\/\"?"},{"key":"coi250076r10","unstructured":"The Public Health Agency of Sweden. National Vaccination Register. 2019. Accessed May 6, 2025. https:\/\/www.folkhalsomyndigheten.se\/smittskydd-beredskap\/vaccinationer\/nationella-vaccinationsregistret\/"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2843054\/jamaoncology_deng_2025_oi_250076_1771446069.53536.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T16:01:10Z","timestamp":1771516870000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2843054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,1]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2025.5511","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,1]]}}}